{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:14:25Z","timestamp":1783437265236,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020604","name":"Novartis Portugal","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41433-026-04467-4","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:53:22Z","timestamp":1776430402000},"page":"1567-1575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural, functional and patient-reported 24-month outcomes of voretigene neparvovec in Portuguese patients with RPE65-associated disease"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0727-4886","authenticated-orcid":false,"given":"Telma","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-9328","authenticated-orcid":false,"given":"Miguel","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisete","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lu\u00edsa","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-4415","authenticated-orcid":false,"given":"M\u00e1rio","family":"Alfaiate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3511-1515","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Figueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-0483","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"4467_CR1","doi-asserted-by":"publisher","unstructured":"Garc\u00eda Boh\u00f3rquez B, Aller E, Rodr\u00edguez Mu\u00f1oz A, Jaijo T, Garc\u00eda GG, Mill\u00e1n JM. Updating the genetic landscape of inherited retinal dystrophies. Front Cell Dev Biol. 2021;9. https:\/\/doi.org\/10.3389\/fcell.2021.645600.","DOI":"10.3389\/fcell.2021.645600"},{"key":"4467_CR2","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3390\/ijms22042096","volume":"22","author":"L Olivares-Gonz\u00e1lez","year":"2021","unstructured":"Olivares-Gonz\u00e1lez L, Velasco S, Campillo I, Rodrigo R. Retinal inflammation, cell death and inherited retinal dystrophies. Int J Mol Sci. 2021;22:2096 https:\/\/doi.org\/10.3390\/ijms22042096.","journal-title":"Int J Mol Sci"},{"key":"4467_CR3","unstructured":"Genes and Mapped Loci Causing Retinal Diseases - RetNet: Retinal Information Network. 2025, https:\/\/retnet.org\/ (accessed 10\/02\/2025 2025)."},{"key":"4467_CR4","doi-asserted-by":"publisher","unstructured":"Lorenz B, Tavares J, Van Den Born LI, Marques JP, Pilotto E, Stingl K, et al. Current management of patients with RPE65 mutation associated inherited retinal degenerations in Europe: results of a 2-year follow-up multinational survey. Ophthalmic Res. 2023:727\u201348. https:\/\/doi.org\/10.1159\/000529777.","DOI":"10.1159\/000529777"},{"key":"4467_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","volume":"131","author":"B Lorenz","year":"2024","unstructured":"Lorenz B, K\u00fcnzel SH, Preising MN, Scholz JP, Chang P, Holz FG, et al. Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 mutation\u2013associated inherited retinal degeneration in a clinical setting. Ophthalmology. 2024;131:161\u201378. https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.006.","journal-title":"Ophthalmology"},{"key":"4467_CR6","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.3390\/ijms22137207","volume":"22","author":"M Aoun","year":"2021","unstructured":"Aoun M, Passerini I, Chiurazzi P, Karali M, Rienzo I, Sartor G, et al. Inherited retinal diseases due to RPE65 variants: from genetic diagnostic management to therapy. Int J Mol Sci. 2021;22:7207 https:\/\/doi.org\/10.3390\/ijms22137207.","journal-title":"Int J Mol Sci"},{"key":"4467_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","volume":"6","author":"JD Sengillo","year":"2022","unstructured":"Sengillo JD, Gregori NZ, Sisk RA, Weng CY, Berrocal AM, Davis JL, et al. Visual acuity, retinal morphology, and patients\u2019 perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease. Ophthalmol Retin. 2022;6:273\u201383. https:\/\/doi.org\/10.1016\/j.oret.2021.11.005.","journal-title":"Ophthalmol Retin"},{"key":"4467_CR8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12325-021-02036-7","volume":"39","author":"JMF Sallum","year":"2022","unstructured":"Sallum JMF, Kaur VP, Shaikh J, Banhazi J, Spera CL, Aouadj C, et al. Epidemiology of mutations in the 65-kDa retinal pigment epithelium (RPE65) gene-mediated inherited retinal dystrophies: a systematic literature review. Adv Ther. 2022;39:1179\u201398. https:\/\/doi.org\/10.1007\/s12325-021-02036-7.","journal-title":"Adv Ther"},{"key":"4467_CR9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/biom13101484","volume":"13","author":"P Kiraly","year":"2023","unstructured":"Kiraly P, Cottriall CL, Taylor LJ, Jolly JK, Cehajic-Kapetanovic J, Yusuf IH, et al. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules. 2023;13:1484 https:\/\/doi.org\/10.3390\/biom13101484.","journal-title":"Biomolecules"},{"key":"4467_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41525-025-00475-7","volume":"10","author":"A Marta","year":"2025","unstructured":"Marta A, Marques-Couto P, Vaz-Pereira S, Costa J, Cabral D, Estrela-Silva S, et al. Clinical and genetic landscape of IRD in Portugal: pooled data from the nationwide IRD-PT registry. NPJ Genom Med. 2025;10:11 https:\/\/doi.org\/10.1038\/s41525-025-00475-7.","journal-title":"NPJ Genom Med"},{"key":"4467_CR11","doi-asserted-by":"publisher","unstructured":"Marques JP, Ferreira N, Moreno N, Marta A, Vaz-Pereira S, Estrela-Silva S, et al. Current management of inherited retinal degenerations in Portugal (IRD-PT survey). Sci Rep. 2024;14. https:\/\/doi.org\/10.1038\/s41598-024-72589-4.","DOI":"10.1038\/s41598-024-72589-4"},{"key":"4467_CR12","unstructured":"LESoPC. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/luxturna-epar-product-information_en.pdf."},{"key":"4467_CR13","doi-asserted-by":"publisher","unstructured":"Marques JP, Raimundo M, Paiva C, Figueira J, Alfaite M, Silva R, et al. O Primeiro Tratamento com Luxturna em Portugal: Um Pequeno Passo para a Ci\u00eancia Mundial, um Salto Gigante para a Oftalmologia Portuguesa. Oftalmologia. 2021;45. https:\/\/doi.org\/10.48560\/rspo.24654.","DOI":"10.48560\/rspo.24654"},{"key":"4467_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(17)31868-8.","journal-title":"Lancet"},{"key":"4467_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation\u2013associated inherited retinal dystrophy. Ophthalmology. 2019;126:1273\u201385. https:\/\/doi.org\/10.1016\/j.ophtha.2019.06.017.","journal-title":"Ophthalmology"},{"key":"4467_CR16","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","volume":"260","author":"C Deng","year":"2022","unstructured":"Deng C, Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera TK, et al. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefes Arch Clin Exp Ophthalmol. 2022;260:1543\u201350. https:\/\/doi.org\/10.1007\/s00417-021-05508-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4467_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/biom14010122","volume":"14","author":"MD Fischer","year":"2024","unstructured":"Fischer MD, Simonelli F, Sahni J, Holz FG, Maier R, Fasser C, et al. Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study. Biomolecules. 2024;14:122 https:\/\/doi.org\/10.3390\/biom14010122.","journal-title":"Biomolecules"},{"key":"4467_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"4467_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10633-009-9204-7","volume":"119","author":"M Klein","year":"2009","unstructured":"Klein M, Birch DG. Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Doc Ophthalmol. 2009;119:217\u201324. https:\/\/doi.org\/10.1007\/s10633-009-9204-7.","journal-title":"Doc Ophthalmol"},{"key":"4467_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41433-023-02636-3","volume":"38","author":"LF Shi","year":"2024","unstructured":"Shi LF, Hall AJ, Thompson DA. Full-field stimulus threshold testing: a scoping review of current practice. Eye. 2024;38:33\u201353. https:\/\/doi.org\/10.1038\/s41433-023-02636-3.","journal-title":"Eye"},{"key":"4467_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13816810.2022.2025609","volume":"43","author":"JA-O Marques","year":"2022","unstructured":"Marques JA-O, Bernardes L, Oliveira C, Fonseca G, Gil JQ, Sotero L, et al. Portuguese translation and linguistic validation of the Michigan Retinal Degeneration Questionnaire and the Michigan Vision-Related Anxiety Questionnaire in a cohort with inherited retinal degenerations. Ophthalmic Genet. 2022;43:137\u20139. https:\/\/doi.org\/10.1080\/13816810.2022.2025609.","journal-title":"Ophthalmic Genet"},{"key":"4467_CR22","doi-asserted-by":"publisher","unstructured":"Marques JP, Alfaiate M, Figueira JP. Subretinal bleb of voretigene neparvovec. Asia Pac J Ophthalmol. 2022. https:\/\/doi.org\/10.1097\/APO.0000000000000431.","DOI":"10.1097\/APO.0000000000000431"},{"key":"4467_CR23","doi-asserted-by":"publisher","unstructured":"Testa F, Melillo P, Di Iorio V, Iovino C, Farinaro F, Karali M, et al. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy. Sci Rep. 2022;12. https:\/\/doi.org\/10.1038\/s41598-022-22180-6.","DOI":"10.1038\/s41598-022-22180-6"},{"key":"4467_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/biomedicines11010103","volume":"11","author":"MJ Gerhardt","year":"2022","unstructured":"Gerhardt MJ, Priglinger CS, Rudolph G, Hufendiek K, Framme C, J\u00e4gle H, et al. Gene therapy with voretigene neparvovec improves vision and partially restores electrophysiological function in pre-school children with leber congenital amaurosis. Biomedicines. 2022;11:103 https:\/\/doi.org\/10.3390\/biomedicines11010103.","journal-title":"Biomedicines"},{"key":"4467_CR25","doi-asserted-by":"publisher","unstructured":"Parameswarappa DC, Stephenson KAJ, Seamone M, Qian CX, Muni RH, Kertes PJ, et al. \u201cBlindness\u201d is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases. Canadian J Ophthalmol. 2024. https:\/\/doi.org\/10.1016\/j.jcjo.2024.12.013.","DOI":"10.1016\/j.jcjo.2024.12.013"},{"key":"4467_CR26","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1038\/s41433-023-02411-4","volume":"37","author":"EA-O Rebelo Neves","year":"2023","unstructured":"Rebelo Neves EA-O, Carvalho AL, Mesquita T, Paiva C, Alfaiate M, Figueira J, et al. Bilateral functional worsening following voretigene neparvovec therapy. Eye. 2023;37:2828\u20139. https:\/\/doi.org\/10.1038\/s41433-023-02411-4.","journal-title":"Eye"},{"key":"4467_CR27","doi-asserted-by":"publisher","unstructured":"Kort\u00fcm FC, Kempf M, Jung R, Kohl S, Ott S, Kortuem C, et al. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec. Acta Ophthalmol. 2022;100. https:\/\/doi.org\/10.1111\/aos.14990.","DOI":"10.1111\/aos.14990"},{"key":"4467_CR28","doi-asserted-by":"publisher","first-page":"13756","DOI":"10.3390\/ijms241813756","volume":"24","author":"M Malvasi","year":"2023","unstructured":"Malvasi M, Casillo L, Avogaro F, Abbouda A, Vingolo EM. Gene therapy in hereditary retinal dystrophies: the usefulness of diagnostic tools in candidate patient selections. Int J Mol Sci. 2023;24:13756 https:\/\/doi.org\/10.3390\/ijms241813756.","journal-title":"Int J Mol Sci"},{"key":"4467_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.10.12.27","volume":"10","author":"KE Lee","year":"2021","unstructured":"Lee KE, Heitkotter H, Carroll J. Challenges associated with ellipsoid zone intensity measurements using optical coherence tomography. Transl Vis Sci Technol. 2021;10:27 https:\/\/doi.org\/10.1167\/tvst.10.12.27.","journal-title":"Transl Vis Sci Technol"},{"key":"4467_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","volume":"6","author":"WS Gange","year":"2022","unstructured":"Gange WS, Sisk RA, Besirli CG, Lee TC, Havunjian M, Schwartz H, et al. Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis. Ophthalmol Retin. 2022;6:58\u201364. https:\/\/doi.org\/10.1016\/j.oret.2021.03.016.","journal-title":"Ophthalmol Retin"},{"key":"4467_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","volume":"130","author":"K Stingl","year":"2023","unstructured":"Stingl K, Stingl K, Schwartz H, Reid MW, Kempf M, Dimopoulos S, et al. Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy. Ophthalmology. 2023;130:764\u201370. https:\/\/doi.org\/10.1016\/j.ophtha.2023.02.015.","journal-title":"Ophthalmology"},{"key":"4467_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/bjo-2024-326221","volume":"109","author":"A Daruich","year":"2025","unstructured":"Daruich A, Rateaux M, Batt\u00e9 E, De Vergnes N, Valleix S, Robert MP, et al. 12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy. Br J Ophthalmol. 2025;109:281 https:\/\/doi.org\/10.1136\/bjo-2024-326221.","journal-title":"Br J Ophthalmol"},{"key":"4467_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41433-025-03672-x","volume":"39","author":"P Kiraly","year":"2025","unstructured":"Kiraly P, Ivanova T, Jalil A. Foveal detachment in voretigene neparvovec administration: essential step or avoidable risk?. Eye. 2025;39:810\u20131. https:\/\/doi.org\/10.1038\/s41433-025-03672-x.","journal-title":"Eye"},{"key":"4467_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/0145482X0910300303","volume":"103","author":"JK Bambara","year":"2009","unstructured":"Bambara JK, Wadley V, Owsley C, Martin RC, Porter C, Dreer L. Family functioning and low vision: a systematic review. J Vis Impair Blind. 2009;103:137\u201349.","journal-title":"J Vis Impair Blind"},{"key":"4467_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/aos.16601","volume":"102","author":"JS Karuntu","year":"2024","unstructured":"Karuntu JS, Nguyen XT, Boon CJF. Correlations between the Michigan Retinal Degeneration Questionnaire and visual function parameters in patients with retinitis pigmentosa. Acta Ophthalmol. 2024;102:555\u201363. https:\/\/doi.org\/10.1111\/aos.16601.","journal-title":"Acta Ophthalmol"},{"key":"4467_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2025.100105","volume":"2","author":"S Teixeira","year":"2025","unstructured":"Teixeira S, Franca M, Gouveia N, Teixeira B, Silva R, Murta J, et al. Structural and functional clinician-reported outcomes show strong correlations with patient-reported outcomes in Retinitis Pigmentosa. AJO Int. 2025;2:100105. https:\/\/doi.org\/10.1016\/j.ajoint.2025.100105.","journal-title":"AJO Int"},{"key":"4467_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/13816810.2023.2191708","volume":"44","author":"JP Marques","year":"2023","unstructured":"Marques JP, Machado Soares R, Sim\u00e3o S, Abuzaitoun R, Andrews C, Alves CH, et al. Self-reported visual function and psychosocial impact of visual loss in EYS-associated retinal degeneration in a Portuguese population. Ophthalmic Genet. 2023;44:334\u201340. https:\/\/doi.org\/10.1080\/13816810.2023.2191708.","journal-title":"Ophthalmic Genet"},{"key":"4467_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.65.6.5","volume":"65","author":"B Parekh","year":"2024","unstructured":"Parekh B, Duncan JL, Samarakoon L, Melia M, Abalem MF, Andrews CA, et al. Self-reported functional vision in USH2A-associated retinal degeneration as measured by the Michigan retinal degeneration questionnaire. Invest Ophthalmol Vis Sci. 2024;65:5 https:\/\/doi.org\/10.1167\/iovs.65.6.5.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04467-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:21:44Z","timestamp":1783434104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04467-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04467-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Good Pharmacoepidemiology Practices (ISPE, 2015) and the Declaration of Helsinki, and received approval from the hospital\u2019s Ethics Committee. All participants provided written informed consent prior to enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}